MENU
KROS
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Keros Therapeutics (KROS) Ownership - Who owns Keros Therapeutics?
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs... Show more
Profile
Industry
N/A
Address
1050 Waltham Street
Phone
+1 617 314-6297
Employees
136
Web
https://www.kerostx.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
416.98M
P/E Ratio
N/A
Total Cash
559.93M
Projected Growth
N/A
Total Debt
18.86M
Revenue
3.55M
Risk (Beta)
1.36
Dividend Yield
N/A
Total Cash/Share
13.80
Total Debt/Equity
N/A
Revenue/Share
0.09 USD as % of share price
Fundamentals
KROS
Capitalization
417M
P/E Ratio
N/A
Risk (Beta)
1.36
Dividend Yield
N/A
Total Cash
560M
Total Cash/Share
13.80
Total Debt
18.9M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.09%
Revenue
3.55M
ROE
N/A
Book Value
572M
P/B Ratio
0.73
Cash Flow
N/A
Earnings
-5
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
4K
Current Ratio
21.45
Current Revenue Per Employee
18000.00
Dividends Per Share - Security
N/A
EBITDA
-185.82M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-38.01
Shares Held By Institutions
1.06B
Shares Outstanding - Current
40.6M
Total Liabilities
44.3M
Total Volume MTD
N/A
Value
N/A
Gain YTD
-35.060
View a ticker or compare two or three
VS
VS
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a biopharmaceutical company, which focuses on treatments for rare muscle diseases
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
1050 Waltham Street
Phone
+1 617 314-6297
Employees
136
Web
https://www.kerostx.com